Water chemicals linked to death risk in men with prostate cancer
One chemical had a 1.07 adjusted hazard ratio—a relative death-rate measure—for death from any cause in the second-lowest versus lowest fifth of estimated exposure.
Our read
Populations- Studied:
- Preprint: cohort study of 51,289 men with prostate cancer, against men with lowest-fifth PFOA exposure
- What changed:
- Death from any cause was higher in the second-lowest versus lowest fifth of PFOA exposure (adjusted hazard ratio 1.07)
- The catch:
- Exposure estimates reflected community water systems, not each man’s actual water intake
- In the record:
- The 15th paper on perfluorononanoic acid with results in people; 34 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Among 51,289 New Jersey men diagnosed with prostate cancer from 2006 to 2017, a cohort study examined drinking water chemicals and deaths through 2024. The preprint studied three per- and polyfluoroalkyl substances, a group of chemicals. Researchers estimated concentrations in community water systems and linked them to the men’s address histories.
There were 19,749 deaths. One chemical, perfluorooctanoic acid, was associated with higher death rates from any cause in some exposure groups. It was also associated with higher cardiovascular death rates in the highest versus lowest fifth of exposure. Associations strengthened when researchers used exposure estimates from five years earlier. In that analysis, all three chemicals were associated with higher death rates from any cause.
Why it matters
Men living with prostate cancer may be particularly susceptible to these chemicals because of other illnesses and cancer treatment.
Caveats
Exposure estimates represented community water systems, not each man’s actual water intake. The findings concern men with prostate cancer in New Jersey, not men without the disease.
- Perfluorooctanoic acid
- Perfluorononanoic acid
- Perfluorooctane sulfonate
- Prostate cancer
- Cardiovascular disease
- Humans
The paper
Rutgers Cancer Institute
medRxiv, Nov 12, 2026, Open access, CC BY-NC-ND, Preprint, not yet peer-reviewed
Comments
Be the first to comment.